eFSH in clinical equine practice.

This research article discusses using equine follicle stimulating hormone (eFSH) to support ovarian follicular growth in mares, particularly those on ovulation transition or having difficulties. It provides specific treatment protocols and emphasizes that the hormone aids in superovulation in a standard mare’s reproductive cycle.

Understanding the Role of eFSH in Equine Practice

• This research article primarily focuses on the clinical use of eFSH in horses, specifically mares. eFSH, short for equine follicle-stimulating hormone, is used to induce the growth and development of ovarian follicles in mares.
• Follicles are fruiting bodies that form part of a mare’s natural reproductive cycle. However, some mares may struggle with their reproductive cycles, going through transitional or acyclic stages where normal cycling doesn’t occur. This is where eFSH proves to be useful, aiding such mares to navigate these challenges.
• Additionally, the hormone can be used to induce superovulation in cycling mares. Superovulation refers to the production of multiple mature ovulatory follicles leading to the release of several eggs in one cycle. This is often desirable in breeding programs where multiple embryos are preferred.

The eFSH Treatment Protocol

• The paper suggests a protocol for using eFSH. It suggests administering the hormone in doses of 12.5 mg, twice daily, starting between 5 to 7 days after the mare has ovulated. The treatment typically begins when the diameter of the largest follicle measures between 20 to 25 millimeters.
• Alongside this, prostaglandins should be administered on the second day of eFSH therapy. Prostaglandins are hormones that regulate various bodily functions, including the reproductive system, and can aid follicular development.
• The eFSH treatment is continued for 3 to 5 days, until the follicles reach a size of 35 millimeters or more. This duration ensures that the follicles have ample time to mature properly.
• Following the eFSH treatment, the mare is allowed to ‘coast’ for about 36 hours, a period where no additional hormones are administered, allowing for natural progression. After this ‘coasting’ phase, the hormone human chorionic gonadotropin is given to induce ovulation so that breeding can occur.

This research aids in understanding how specific hormonal treatments can be employed in equine veterinary practice, particularly for solving reproductive issues or enhancing breeding capabilities in mares.